Minerva Neurosciences
NERV
73 hedge funds and large institutions have $238M invested in Minerva Neurosciences in 2018 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 36 increasing their positions, 12 reducing their positions, and 6 closing their positions.
671% more call options, than puts
Call options by funds: $131K | Put options by funds: $17K
200% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 12
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
35% more capital invested
Capital invested by funds: $177M → $238M (+$61.4M)
9% more funds holding
Funds holding: 67 → 73 (+6)
0.19% more ownership
Funds ownership: 9.11% → 9.3% (+0.19%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JG
Jefferies Group
New York
|
+$2.43M |
| 2 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
+$1.94M |
| 3 |
BlackRock
New York
|
+$1.67M |
| 4 |
MCM
Moore Capital Management
New York
|
+$1.52M |
| 5 |
Renaissance Technologies
New York
|
+$944K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$4.08M |
| 2 |
AG
Artal Group
Luxembourg
|
-$1.88M |
| 3 |
JP Morgan Chase
New York
|
-$1.56M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.07M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$606K |
NERV Hedge Fund Activity: Q2 2018 in Review
73 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q2 2018, worth a combined $238M — up 35% from $177M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new NERV positions and 6 closed out — a net gain of 6 holders — while 36 added to existing stakes and 12 trimmed.
The largest buyer was Jefferies Group, opening a new position worth an estimated $2.43M. The largest seller was Highland Capital Management (Texas), cutting an estimated $4.08M.
- 73 institutional investors held Minerva Neurosciences (NERV) as of Q2 2018, up from 67 in Q1 2018.
- Funds reported $238M of Minerva Neurosciences stock for Q2 2018, up 35% quarter-over-quarter.
- 12 funds opened new Minerva Neurosciences positions in Q2 2018 and 6 closed out, a net change of +6 holders.
- The largest Minerva Neurosciences buyer in Q2 2018 was Jefferies Group, an estimated $2.43M added.
- The largest Minerva Neurosciences seller in Q2 2018 was Highland Capital Management (Texas), an estimated $4.08M sold.
Based on aggregated 13F filings for Q2 2018.